AR074724A1 - Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno - Google Patents

Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno

Info

Publication number
AR074724A1
AR074724A1 ARP090104834A ARP090104834A AR074724A1 AR 074724 A1 AR074724 A1 AR 074724A1 AR P090104834 A ARP090104834 A AR P090104834A AR P090104834 A ARP090104834 A AR P090104834A AR 074724 A1 AR074724 A1 AR 074724A1
Authority
AR
Argentina
Prior art keywords
citrate salt
triaza
dioxa
tetraciclo
heptacose
Prior art date
Application number
ARP090104834A
Other languages
English (en)
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of AR074724A1 publication Critical patent/AR074724A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

También a composiciones farmacéuticas que contienen la sal de citrato y métodos de uso de la sal de citrato en el tratamiento de ciertas condiciones médicas como trastornos proliferativos. Reivindicación 1: Una sal de citrato caracterizada por ser 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno de formula (1)
ARP090104834A 2008-12-11 2009-12-11 Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno AR074724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11

Publications (1)

Publication Number Publication Date
AR074724A1 true AR074724A1 (es) 2011-02-09

Family

ID=41666397

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090104834A AR074724A1 (es) 2008-12-11 2009-12-11 Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno
ARP190100701A AR114133A2 (es) 2008-12-11 2019-03-20 Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190100701A AR114133A2 (es) 2008-12-11 2019-03-20 Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Country Status (24)

Country Link
US (2) US8980873B2 (es)
EP (1) EP2376499B1 (es)
JP (1) JP5669748B2 (es)
KR (1) KR101729918B1 (es)
CN (1) CN102282148B (es)
AR (2) AR074724A1 (es)
AU (1) AU2009325147B2 (es)
BR (1) BRPI0922736B1 (es)
CA (1) CA2746058C (es)
DK (1) DK2376499T3 (es)
ES (1) ES2536558T3 (es)
HK (1) HK1161877A1 (es)
HR (1) HRP20150428T1 (es)
IL (3) IL213418A0 (es)
MX (1) MX2011006206A (es)
MY (1) MY160005A (es)
NZ (1) NZ593223A (es)
PL (1) PL2376499T3 (es)
PT (1) PT2376499E (es)
RU (1) RU2527970C2 (es)
SG (1) SG171907A1 (es)
TW (1) TWI449705B (es)
WO (1) WO2010068181A1 (es)
ZA (1) ZA201104032B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5669748B2 (ja) 2008-12-11 2015-02-12 シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩
US8987243B2 (en) * 2008-12-11 2015-03-24 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
KR101673979B1 (ko) 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
JP4137645B2 (ja) * 2001-05-14 2008-08-20 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンのクエン酸塩及びその医薬組成物
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
ES2258652T3 (es) * 2001-11-29 2006-09-01 Pfizer Products Inc. Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
WO2007058628A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Heteroalkyl linked pyrimidine derivatives
JP5669748B2 (ja) 2008-12-11 2015-02-12 シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩

Also Published As

Publication number Publication date
BRPI0922736B1 (pt) 2022-02-22
PL2376499T3 (pl) 2015-07-31
KR20110106344A (ko) 2011-09-28
US20150322084A1 (en) 2015-11-12
TW201028426A (en) 2010-08-01
US20110294831A1 (en) 2011-12-01
BRPI0922736A8 (pt) 2021-11-09
AU2009325147A1 (en) 2011-06-23
BRPI0922736A2 (pt) 2017-10-31
ZA201104032B (en) 2012-08-29
MX2011006206A (es) 2011-07-20
NZ593223A (en) 2013-08-30
RU2011126173A (ru) 2013-01-20
CA2746058A1 (en) 2010-06-17
AU2009325147B2 (en) 2014-08-14
JP2012511571A (ja) 2012-05-24
WO2010068181A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
DK2376499T3 (en) 2015-05-04
MY160005A (en) 2017-02-15
SG171907A1 (en) 2011-07-28
TWI449705B (zh) 2014-08-21
IL250310A0 (en) 2017-03-30
WO2010068181A8 (en) 2011-08-18
HRP20150428T1 (en) 2015-06-19
CA2746058C (en) 2016-05-17
CN102282148B (zh) 2014-12-24
JP5669748B2 (ja) 2015-02-12
US8980873B2 (en) 2015-03-17
EP2376499A1 (en) 2011-10-19
CN102282148A (zh) 2011-12-14
US9624242B2 (en) 2017-04-18
EP2376499B1 (en) 2015-02-25
PT2376499E (pt) 2015-06-03
IL213418A0 (en) 2011-07-31
RU2527970C2 (ru) 2014-09-10
IL289379A (en) 2022-02-01
HK1161877A1 (en) 2012-08-10
ES2536558T3 (es) 2015-05-26
KR101729918B1 (ko) 2017-04-25

Similar Documents

Publication Publication Date Title
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CL2011003192A1 (es) Acido (2s)-3-(2-fluoro-5-(5-fluoro-1h-pirrolo[2,3-b]piridin-3-il)fenilamino)biciclo[2.2.2]octano-2-carboxilico; metodo para prepararlo; composicion farmaceutica que lo comprende; y su uso en el tratamiento de la influenza; metodo para reducir el virus de la influenza in vitro.
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MY149731A (en) Compounds
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
MX339644B (es) Sales de xantilio 3,6-disustituidas.
AR084832A1 (es) Derivado cristalino de oxazina
AR074724A1 (es) Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
EA201200838A1 (ru) Средство для лечения болезни паркинсона
AR074725A1 (es) Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19- dioxa-5,7,26-triaza-tetraciclo(19.3.1.1 (2,6).1 (8,12) heptacosa-1(25),2 (26),3,5,8,10,12 (27),16,21,23-decaeno
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
RU2009132625A (ru) Способ лечения заболеваний, вызываемых вирусом герпеса
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.

Legal Events

Date Code Title Description
FC Refusal